Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country: OR Search for:  Show organisations

  General information for Nigeria


Nigeria
Continent: Africa
Capital: Abuja
Population: 154000000
Area (in sq km): 923768.0

Haemoglobinopathy-specific healthcare policy information for Nigeria

Healthcare policyComment/InfoReference
Prevention programme: Yes (National)
SCD newborn screening: NoIt is practiced at subnational level and is generally provided only in tertiary health facilities [AFR/RC70/INF.DOC/3; 30July2020]. Several pilot programmes and as part of the Consortium on Newborn Screening in Africa (CONSA). Six government-sponsored SCD Centers were established in 2012 for NBS (one in each zone of the country).[PMID: 34171276]
Prenatal screening: Yes (Regional)Sickle Cell Foundation Nigeria. Service is available in a few health facilities but expensive.
Antenatal screening: Yes (National)Most secondary and tertiary health care facilities screen for sickle cell disease
Haemoglobinopathies patient registry: NoSickle Cell Disorder Registry Nigeria (SCDRN), an initiative of Sickle Cell Foundation Nigeria and PointCareHealth Initiative (Rhieos -Ventures) based in Netherlands. Also, Sickle Pan Africa Research Consortium Nigeria database.[PMID: 31649726]
Rare disease patient registry: No
Dedicated treatment centres: Yes (National)The National Sickle Cell Centre (NSCC) is located in Lagos, with the goal of developing a Sickle Cell Centre in each State of the Federation. SCD patients are generally cared for in the secondary and tertiary institutions. Ten SCD treatment centres.
Blood transfusion availability: Yes (National)Blood transfusion practices for patients with sickle cell disease in Nigeria. International Health, March 2016[PMID: 27008896]
Iron chelation availability: Yes (National)This is available only to those who can afford it in tertiary health care facilities.
MRI facilities: Yes (National)Most institutions have access to CT and MRI facilities.[PMID: 24114193]
Patient associations: Yes (National)Several exist and are mainly NGOs.
Genetic counselling: Yes (National)Informally at the point of care.

  Prevalence and incidence of major haemoglobinopathies in Nigeria

HaemoglobinopathyComment/InfoReference
Prevalence of β-thalassaemia carriers: 0.8 % of the population[PMID: 5453916]
Prevalence of sickle cell disease carriers: 20.7 % of the populationRanges between 20% and 30% across publications.[PMID: 26633548]
Prevalence of α-thalassaemia carriers: 30 % of the population20-30%
Prevalence of Hb C carriers: 1.1 % of the population[PMID: 26633548]
Incidence of sickle cell disease: 200000 affected births/year

  Global Burden of Disease data for Nigeria

  Migration data for Nigeria

Mutation frequencies in Nigeria

No mutation frequencies are currently available for Nigeria

  Organisations in Nigeria

A list of all organisations in Nigeria stored in the ITHANET database is shown below. For more information, click on the corresponding organisation name or visit the detailed ITHANET Organisations page

NameDepartmentOrganisation type
Sickle Cell Support Society of Nigeria (SCSSN)Research Center, Patient Society

 Microattributions

A/AContributor(s)DateComments
1Nnodu, Obiageli2016-10-29Information on healthcare policies and the status of major haemoglobinopathies reviewed and updated.
2Elion, Jacques2017-10-17Information on SCD newborn screening reviewed.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.